180 related articles for article (PubMed ID: 37216921)
1. Crinecerfont, a CRF1 Receptor Antagonist, Lowers Adrenal Androgens in Adolescents With Congenital Adrenal Hyperplasia.
Newfield RS; Sarafoglou K; Fechner PY; Nokoff NJ; Auchus RJ; Vogiatzi MG; Jeha GS; Giri N; Roberts E; Sturgeon J; Chan JL; Farber RH
J Clin Endocrinol Metab; 2023 Oct; 108(11):2871-2878. PubMed ID: 37216921
[TBL] [Abstract][Full Text] [Related]
2. Crinecerfont Lowers Elevated Hormone Markers in Adults With 21-Hydroxylase Deficiency Congenital Adrenal Hyperplasia.
Auchus RJ; Sarafoglou K; Fechner PY; Vogiatzi MG; Imel EA; Davis SM; Giri N; Sturgeon J; Roberts E; Chan JL; Farber RH
J Clin Endocrinol Metab; 2022 Feb; 107(3):801-812. PubMed ID: 34653252
[TBL] [Abstract][Full Text] [Related]
3. Phase 3 Trial of Crinecerfont in Pediatric Congenital Adrenal Hyperplasia.
Sarafoglou K; Kim MS; Lodish M; Felner EI; Martinerie L; Nokoff NJ; Clemente M; Fechner PY; Vogiatzi MG; Speiser PW; Auchus RJ; Rosales GBG; Roberts E; Jeha GS; Farber RH; Chan JL;
N Engl J Med; 2024 Jun; ():. PubMed ID: 38828945
[TBL] [Abstract][Full Text] [Related]
4. Tildacerfont in Adults With Classic Congenital Adrenal Hyperplasia: Results from Two Phase 2 Studies.
Sarafoglou K; Barnes CN; Huang M; Imel EA; Madu IJ; Merke DP; Moriarty D; Nakhle S; Newfield RS; Vogiatzi MG; Auchus RJ
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4666-e4679. PubMed ID: 34146101
[TBL] [Abstract][Full Text] [Related]
5. Single-Dose Study of a Corticotropin-Releasing Factor Receptor-1 Antagonist in Women With 21-Hydroxylase Deficiency.
Turcu AF; Spencer-Segal JL; Farber RH; Luo R; Grigoriadis DE; Ramm CA; Madrigal D; Muth T; O'Brien CF; Auchus RJ
J Clin Endocrinol Metab; 2016 Mar; 101(3):1174-80. PubMed ID: 26751191
[TBL] [Abstract][Full Text] [Related]
6. Phase 3 Trial of Crinecerfont in Adult Congenital Adrenal Hyperplasia.
Auchus RJ; Hamidi O; Pivonello R; Bancos I; Russo G; Witchel SF; Isidori AM; Rodien P; Srirangalingam U; Kiefer FW; Falhammar H; Merke DP; Reisch N; Sarafoglou K; Cutler GB; Sturgeon J; Roberts E; Lin VH; Chan JL; Farber RH;
N Engl J Med; 2024 Jun; ():. PubMed ID: 38828955
[TBL] [Abstract][Full Text] [Related]
7. 3 alpha-androstanediol glucuronide in virilizing congenital adrenal hyperplasia: a useful serum metabolic marker of integrated adrenal androgen secretion.
Pang S; MacGillivray M; Wang M; Jeffries S; Clark A; Rosenthal I; Wiegensberg M; Riddick L
J Clin Endocrinol Metab; 1991 Jul; 73(1):166-74. PubMed ID: 2045467
[TBL] [Abstract][Full Text] [Related]
8. Glucocorticoid replacement regimens for treating congenital adrenal hyperplasia.
Ng SM; Stepien KM; Krishan A
Cochrane Database Syst Rev; 2020 Mar; 3(3):CD012517. PubMed ID: 32190901
[TBL] [Abstract][Full Text] [Related]
9. Androgen excess is due to elevated 11-oxygenated androgens in treated children with congenital adrenal hyperplasia.
Kamrath C; Wettstaedt L; Boettcher C; Hartmann MF; Wudy SA
J Steroid Biochem Mol Biol; 2018 Apr; 178():221-228. PubMed ID: 29277706
[TBL] [Abstract][Full Text] [Related]
10. Abiraterone acetate to lower androgens in women with classic 21-hydroxylase deficiency.
Auchus RJ; Buschur EO; Chang AY; Hammer GD; Ramm C; Madrigal D; Wang G; Gonzalez M; Xu XS; Smit JW; Jiao J; Yu MK
J Clin Endocrinol Metab; 2014 Aug; 99(8):2763-70. PubMed ID: 24780050
[TBL] [Abstract][Full Text] [Related]
11. Hormonal circadian rhythms in patients with congenital adrenal hyperplasia: identifying optimal monitoring times and novel disease biomarkers.
Debono M; Mallappa A; Gounden V; Nella AA; Harrison RF; Crutchfield CA; Backlund PS; Soldin SJ; Ross RJ; Merke DP
Eur J Endocrinol; 2015 Dec; 173(6):727-37. PubMed ID: 26340969
[TBL] [Abstract][Full Text] [Related]
12. Salivary Profiles of 11-oxygenated Androgens Follow a Diurnal Rhythm in Patients With Congenital Adrenal Hyperplasia.
Nowotny HF; Auer MK; Lottspeich C; Schmidt H; Dubinski I; Bidlingmaier M; Adaway J; Hawley J; Keevil B; Reisch N
J Clin Endocrinol Metab; 2021 Oct; 106(11):e4509-e4519. PubMed ID: 34165575
[TBL] [Abstract][Full Text] [Related]
13. Congenital Adrenal Hyperplasia: Time to Replace 17OHP with 21-Deoxycortisol.
Miller WL
Horm Res Paediatr; 2019; 91(6):416-420. PubMed ID: 31450227
[TBL] [Abstract][Full Text] [Related]
14. Adult manifestation of congenital adrenal hyperplasia due to incomplete 21-hydroxylase deficiency mimicking polycystic ovarian disease.
Lobo RA; Goebelsmann U
Am J Obstet Gynecol; 1980 Nov; 138(6):720-6. PubMed ID: 6254362
[TBL] [Abstract][Full Text] [Related]
15. Clinical advances in the pharmacotherapy of congenital adrenal hyperplasia.
Prete A; Auchus RJ; Ross RJ
Eur J Endocrinol; 2021 Nov; 186(1):R1-R14. PubMed ID: 34735372
[TBL] [Abstract][Full Text] [Related]
16. HLA and hormonal studies in 5 patients with late-onset 21-hydroxylase deficiency syndrome (21OHDS).
Scaroni C; Orlandini E; Venturi Pasini C; Gangemi M; Mantero F
J Endocrinol Invest; 1986 Feb; 9(1):65-70. PubMed ID: 3009598
[TBL] [Abstract][Full Text] [Related]
17. A Phase 2, Multicenter Study of Nevanimibe for the Treatment of Congenital Adrenal Hyperplasia.
El-Maouche D; Merke DP; Vogiatzi MG; Chang AY; Turcu AF; Joyal EG; Lin VH; Weintraub L; Plaunt MR; Mohideen P; Auchus RJ
J Clin Endocrinol Metab; 2020 Aug; 105(8):2771-8. PubMed ID: 32589738
[TBL] [Abstract][Full Text] [Related]
18. Steroid 17-Hydroxyprogesterone in Hair Is a Potential Long-Term Biomarker of Androgen Control in Congenital Adrenal Hyperplasia due to 21-Hydroxylase Deficiency.
Auer MK; Krumbholz A; Bidlingmaier M; Thieme D; Reisch N
Neuroendocrinology; 2020; 110(11-12):938-949. PubMed ID: 31711056
[TBL] [Abstract][Full Text] [Related]
19. Androgens concentrations and second-to fourth-digit ratio (2D:4D) in girls with congenital adrenal hyperplasia (21-hydroxylase deficiency).
Oswiecimska JM; Ksiazek A; Sygulla K; Pys-Spychala M; Roczniak GR; Roczniak W; Stojewska M; Ziora K
Neuro Endocrinol Lett; 2012; 33(8):787-91. PubMed ID: 23391972
[TBL] [Abstract][Full Text] [Related]
20. [Congenital adrenal hyperplasia due to 21-hydroxylase deficiency--management in adults].
Ambroziak U; Bednarczuk T; Ginalska-Malinowska M; Małunowicz EM; Grzechocińska B; Kamiński P; Bablok L; Przedlacki J; Bar-Andziak E
Endokrynol Pol; 2010; 61 Suppl 1():7-21. PubMed ID: 22127631
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
